3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Approved for marketing
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
19
Observational
6
Expanded_access
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
1
Interventions
nilotinib
4
ruxolitinib
2
ponatinib
2
venetoclax
1
selinexor
1
navitoclax
1
midostaurin
1
fludarabine phosphate
1
asciminib
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Mycophenolic Acid
1
Imatinib Mesylate
1
Dasatinib
1
Cytarabine
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Expanded_access
×
ponatinib
×
Myeloid
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT01549548
2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available